Royalty Pharma plc financial data

Symbol
RPRX on Nasdaq
Location
110 East 59 Th Street, New York, New York
State of incorporation
United Kingdom
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 474 % +54.5%
Return On Equity 8.12 % +146%
Return On Assets 4.88 % +155%
Operating Margin 42 % +74.8%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 13.7B USD -25.9%
Weighted Average Number of Shares Outstanding, Basic 449M shares +0.68%
Weighted Average Number of Shares Outstanding, Diluted 597M shares -1.61%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.24B USD -5.11%
Research and Development Expense 52M USD -32.6%
General and Administrative Expense 222M USD -15.2%
Costs and Expenses 1.3B USD -27.5%
Operating Income (Loss) 939M USD +65.9%
Nonoperating Income (Expense) 247M USD +453%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1.19B USD +94.2%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent 799M USD +141%
Earnings Per Share, Basic 1.79 USD/shares +142%
Earnings Per Share, Diluted 1.78 USD/shares +141%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 843M USD -57.3%
Other Assets, Current 5.01M USD +9.63%
Assets, Current 1.56B USD -40.7%
Other Assets, Noncurrent 4.49M USD -84%
Assets 16.1B USD -5.52%
Liabilities, Current 125M USD -88.8%
Other Liabilities, Noncurrent 3.22M USD
Liabilities 6.27B USD -13.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD -100%
Retained Earnings (Accumulated Deficit) 2.43B USD +9.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 9.86B USD +0.43%
Liabilities and Equity 16.1B USD -5.52%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 665M USD -35.7%
Net Cash Provided by (Used in) Financing Activities -212M USD -0.77%
Net Cash Provided by (Used in) Investing Activities -86.7M USD +84.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 366M USD +38.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 843M USD -57.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 79M USD -4.38%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 1.13B USD +4401%
Additional Paid in Capital 4.07B USD +8.96%
Amortization of Intangible Assets 0 USD -100%
Share-based Payment Arrangement, Expense 2.9M USD -22.2%
Interest Expense 184M USD -1.8%